Adenocarcinoma In Situ C0334276
A non-invasive cancer confined to glandular cells, commonly in the lung or cervix. Early detection allows effective treatment with surgery or local procedures.
Key facts at a glance
- ICD-10
- C80.1
- ICD-11
- 2A00.0
- Body system
- oncologic
- Severity
- mild
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Rectal bleeding
Abdominal fullness
(gastrointestinal)Generalized symptoms
(oncologic)Mild symptoms that may not significantly impact daily life.
Frequency: Common at all stages
Early satiety
(gastrointestinal)Change in bowel habits
(gastrointestinal)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Excisional Biopsy with Clear Margins
Complete surgical removal of the adenocarcinoma in situ with adequate margins to ensure complete excision and reduce recurrence risk.
Healthy lifestyle changes and stress management
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Endoscopic Mucosal Resection
Minimally invasive procedure using endoscopic techniques to remove localized in situ adenocarcinoma, preserving surrounding healthy tissue.
Additional treatment options
Enhanced Surveillance Protocol
Close follow-up with regular imaging, endoscopic evaluation, and tumor markers to detect any recurrence or progression early.
monitoringSmoking Cessation and Alcohol Reduction
Elimination of tobacco use and reduction of alcohol consumption which are known risk factors for adenocarcinoma progression and recurrence.
lifestyleAnti-Inflammatory Nutrition
Diet rich in antioxidants, fiber, and anti-inflammatory foods to support immune function and potentially reduce cancer progression risk.
dietaryWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Adenocarcinoma In Situ C0334276?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Travis WD, Pelosi G, Mino-Kenudson M. WHO Classification of Lung Tumors: Adenocarcinoma In Situ. J Thorac Oncol. 2023;18(4):456-472.
Nicholson AG, Brambilla E, Dacic S. Adenocarcinoma In Situ: Pathology, Molecular Features, and Clinical Significance. Arch Pathol Lab Med. 2022;146(8):945-961.
Yoshizawa A, Honda K, Hata M. Survival Outcomes After Limited Resection for Adenocarcinoma In Situ: A Systematic Review and Meta-Analysis. Ann Thorac Surg. 2021;112(5):1523-1533.
Cagle PT, Allen TC, Olsen RJ. Adenocarcinoma In Situ. In: Color Atlas of Pulmonary Pathology. 3rd ed. Philadelphia: Elsevier; 2020:312-328.
Medication Comparisons
Compare medications used to treat Adenocarcinoma In Situ C0334276. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 27, 2026. · Read our editorial policy